DU‐145 prostate cancer cells showed an extraordinary 40‐fold increase in sensitivity to c‐Myc‐i7 compared to 10058‐F4, with c‐Myc‐i10 also demonstrating significant improvements. This evidence concerns the gene MYC and prostate carcinoma.